Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Jump-Start Your Search For Promising Trade Ideas With Barchart Premier’s "Top Stock Pick". FREE 30 Day Trial
Stocks | Futures | Watchlist | More
or

Bellicum Pharmaceuticals Inc (BLCM)

Bellicum Pharmaceuticals Inc (BLCM)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [OTC US]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [OTC US]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]

Fundamentals

See More
  • Market Capitalization, $K 727
  • Shares Outstanding, K 9,717
  • Annual Sales, $ 1,500 K
  • Annual Income, $ -24,970 K
  • 60-Month Beta 1.39
  • Price/Sales 12.72
  • Price/Cash Flow N/A
  • Price/Book N/A
Trade BLCM with:
  • Price/Earnings ttm 0.00
  • Earnings Per Share ttm -0.52
  • Most Recent Earnings $-0.02 on 11/14/23
  • Latest Earnings Date 03/05/24
  • Annual Dividend & Yield N/A (0.00%)
  • Most Recent Dividend N/A on N/A
  • Sectors:

Price Performance

See More
Period Period Low Period High Performance
1-Month
0.0701 +6.70%
on 02/23/24
0.1097 -31.81%
on 02/07/24
-0.0053 (-6.62%)
since 02/02/24
3-Month
0.0650 +15.08%
on 01/29/24
0.2491 -69.97%
on 12/08/23
-0.1752 (-70.08%)
since 12/04/23
52-Week
0.0600 +24.67%
on 11/09/23
1.3100 -94.29%
on 05/08/23
-0.7732 (-91.18%)
since 03/03/23

Most Recent Stories

More News
Bellicum (BLCM) Down on Ending Development of CAR-T Candidates

Following the decision to discontinue the development of pipeline candidates, Bellicum Pharmaceuticals (BLCM) is left with no candidate in clinical development. The stock is down 50% post the news.

ADPT : 3.18 (-1.85%)
BLCM : 0.0748 (-6.62%)
CRSP : 71.47 (-2.03%)
EQRX : 2.34 (-2.09%)
Is Bellicum Pharmaceuticals (BLCM) Stock Outpacing Its Medical Peers This Year?

Here is how Bellicum Pharmaceuticals (BLCM) and Chemed (CHE) have performed compared to their sector so far this year.

BLCM : 0.0748 (-6.62%)
CHE : 649.04 (+0.32%)
Is Bellicum Pharmaceuticals (BLCM) Outperforming Other Medical Stocks This Year?

Here is how Bellicum Pharmaceuticals (BLCM) and Castle Biosciences, Inc. (CSTL) have performed compared to their sector so far this year.

BLCM : 0.0748 (-6.62%)
CSTL : 18.94 (+0.50%)
Bellicum Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

HOUSTON, July 01, 2022 (GLOBE NEWSWIRE) -- Bellicum Pharmaceuticals, Inc. (NASDAQ:BLCM), a leader in developing novel, controllable cellular...

BLCM : 0.0748 (-6.62%)
Bellicum Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

HOUSTON, May 02, 2022 (GLOBE NEWSWIRE) -- Bellicum Pharmaceuticals, Inc. (NASDAQ:BLCM), a leader in developing novel, controllable cellular...

BLCM : 0.0748 (-6.62%)
Bellicum Reports Fourth Quarter 2021 Financial Results and Provides Operational Update

- Confirmed partial response in one of the first three metastatic castration-resistant prostate cancer (mCRPC) patients treated with BPX-601 in Phase 1/2...

BLCM : 0.0748 (-6.62%)
Bellicum Pharmaceuticals to Participate in the B. Riley Securities 2022 Virtual Oncology Conference

HOUSTON, Jan. 26, 2022 (GLOBE NEWSWIRE) -- Bellicum Pharmaceuticals, Inc. (Nasdaq: BLCM), a leader in developing novel, controllable cellular...

BLCM : 0.0748 (-6.62%)
Bellicum Regains Compliance with Nasdaq Continued Listing Requirements

HOUSTON, Dec. 13, 2021 (GLOBE NEWSWIRE) -- Bellicum Pharmaceuticals, Inc. (Nasdaq: BLCM), a leader in developing novel, controllable cellular...

BLCM : 0.0748 (-6.62%)
Bellicum Reports Third Quarter 2021 Financial Results and Provides Operational Update

- Entered into additional licensing agreement with The University of Texas MD Anderson Cancer Center for use of CaspaCIDe® safety switch technology - -...

BLCM : 0.0748 (-6.62%)
Bellicum Pharmaceuticals to Participate in the H.C. Wainwright 23rd Annual Global Investment Conference

HOUSTON, Sept. 03, 2021 (GLOBE NEWSWIRE) -- Bellicum Pharmaceuticals, Inc. (NASDAQ:BLCM), a leader in developing novel, controllable cellular immunotherapies for cancers, today announced that Rick Fair,...

BLCM : 0.0748 (-6.62%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 100% Sell with a Strengthening short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Key Turning Points

3rd Resistance Point 0.1043
2nd Resistance Point 0.0971
1st Resistance Point 0.0860
Last Price 0.0748
1st Support Level 0.0677
2nd Support Level 0.0605
3rd Support Level 0.0494

See More

52-Week High 1.3100
Fibonacci 61.8% 0.8325
Fibonacci 50% 0.6850
Fibonacci 38.2% 0.5375
Last Price 0.0748
52-Week Low 0.0600

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar